Notice is hereby given that the Annual General Meeting ("AGM") of TyraTech, Inc. (AIM: TYR), will be held on 21 May 2009 at 12.00 noon (GMT) at the office of Buchanan Communications, 45 Moorfields, London EC2Y 9AE. You will be asked to consider and vote on the resolutions below. All of the resolutions will be proposed as ordinary resolutions.
Ordinary Business
To consider and, if thought fit, pass the following ordinary resolutions:
Stockholders of record of the Company at the close of business on 22 April 2009 are entitled to vote at the AGM and any postponements or adjournments of the meeting. A list of these stockholders is available at the offices of the Company at the following address in 1901 S. Harbor City Blvd, Suite 300, Melbourne, Florida, 32901, USA.
By order of the Board
Keith E. Bigsby
Company Secretary
1 April 2009
Notes
For further information please contact:
TyraTech Inc. Alan Reade, Executive Chairman www.tyratech.com |
1 (321) 409 - 7720 |
Nomura Code Securities Charles Walker/Clare Terlouw www.nomuracode.com |
+44 (0)20 7776 1200 |
Buchanan Communications Mary-Jane Johnson/Lisa Baderoon/ Catherine Breen/Stasa Filiplic www.buchanan.uk.com |
+44 (0) 20 7466 5000 |
About TyraTech
TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company’s proprietary technology. TyraTech, which already has products on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech’s technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech’s platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.
TyraTech is actively developing selected proprietary active ingredients which can then be used for various products across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for an insect/mosquito repellent. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.
TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium.
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.